Social media gurus Gwee and Monseau move on to new jobs

Share this article:
Shwen Gwee
Shwen Gwee
Two of the drug industry's top social media experts, Shwen Gwee and Marc Monseau, are changing jobs.

Shwen Gwee is leaving Vertex to co-lead Edelman's digital health practice.

Gwee, one of the drug industry's top digital and social media gurus, will work out of Edelman's New York office and report to Bruce Hayes, general manager of Edelman's New York healthcare practice, where he'll join former AstraZeneca marketer Gigi Peterkin. Gwee was digital strategy and social media lead at Vertex for several years and also co-founded the Social Health Unconference and the SocialPharmer Network. He's also a member of MM&M's editorial advisory board.

Gwee said on his Med2.0 blog: “While I was able to roll out some cool and interesting digital initiatives during my time at Vertex, my new role at Edelman will allow me to serve the industry in a greater capacity and spread my wings more broadly by challenging me to think across multiple audiences, diseases, and brands/clients.”

Monseau, who has been with J&J for 14 years, including three as director of corporate communication and social media, is leaving the company to open up his own firm, MDM Communications, which "will provide social and digital communication support focusing on healthcare and related industries to help companies become more involved in the social web," he told MM&M.

Gwee and Monseau will hold a live discussion entitled “We've got your social media guidelines right here” at the inaugural MM&M Virtual Summit on May 24. To register for free, click here.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.